Skip to content

Efficacy verification test for continuous use of hair growth agent (AH2C)

Efficacy verification test for continuous use of hair growth agent (AH2C) - ACJ-01

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045852
Enrollment
60
Registered
2021-11-14
Start date
2021-11-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thinning hair

Interventions

Use hair growth products (Sample-P) twice daily for up to 24 weeks. Phototrichograms will be performed prior to dosing, after 12 weeks of dosing, and after 24 weeks of dosing. Use hair growth products

Sponsors

ADJUVANT COSME JAPAN
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) Japanese males between 30 and 60 years of age (2) Patients with thinning hair equivalent to Hamilton-Norwood classification II-IV (including Type A and Vertex) as of the date of consent. (3) Subjects who have been explained the purpose and content of the research prior to the research, and who have the capacity to make decisions and have given written consent from the research subject.

Exclusion criteria

Exclusion criteria: (1) Persons who have hair transplantation or wear wigs (2) Persons who may show allergic symptoms to the components of the test substance (3) Those who may show allergic symptoms to skin or those who have skin hypersensitivity Those who have a history of serious heart disease, renal disease, liver disease, or cancer, or those who have thyroid dysfunction. 5) Those who have not used health foods, cosmetics, quasi-drugs, or medicines (e.g., hair-growth products) that may affect the test results for more than 6 months. (6) Others whom the principal investigator judges to be inappropriate for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Percent change in hair diameter after 24 weeks of treatment

Countries

Japan

Contacts

Public ContactHiromu Katsuta

ReLife-inc Clinical Development Division

hkatsuta@relife-inc.com03-5928-2501

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026